Vor Biopharma Inc. (NYSE:VOR) Given Consensus Rating of “Buy” by Analysts

Vor Biopharma Inc. (NYSE:VOR) has been given an average recommendation of “Buy” by the seven research firms that are presently covering the company, MarketBeat reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokers that have covered the stock in the last year is $11.36.

Several equities research analysts recently weighed in on the stock. Barclays reduced their price target on shares of Vor Biopharma from $10.00 to $3.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 14th. HC Wainwright reissued a “buy” rating and issued a $17.50 price objective on shares of Vor Biopharma in a research note on Friday, November 8th. JMP Securities reaffirmed a “market outperform” rating and issued a $12.00 price target on shares of Vor Biopharma in a report on Friday, September 6th. Robert W. Baird reduced their price objective on Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating on the stock in a research note on Friday, November 8th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $11.00 price objective on shares of Vor Biopharma in a research note on Friday, November 8th.

Hedge Funds Weigh In On Vor Biopharma

Several hedge funds have recently bought and sold shares of the business. Hsbc Holdings PLC boosted its holdings in shares of Vor Biopharma by 177.0% in the second quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock valued at $51,000 after purchasing an additional 31,333 shares during the period. Cubist Systematic Strategies LLC bought a new position in shares of Vor Biopharma during the 2nd quarter worth $53,000. Acadian Asset Management LLC purchased a new position in shares of Vor Biopharma during the first quarter valued at $126,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Vor Biopharma in the second quarter valued at about $63,000. Finally, Rosalind Advisors Inc. purchased a new stake in Vor Biopharma in the third quarter worth about $54,000. Institutional investors own 97.29% of the company’s stock.

Vor Biopharma Stock Performance

Shares of NYSE:VOR opened at $0.80 on Friday. The firm has a market cap of $54.67 million, a price-to-earnings ratio of -0.48 and a beta of -0.40. The firm has a fifty day moving average price of $0.78 and a 200 day moving average price of $1.02. Vor Biopharma has a fifty-two week low of $0.63 and a fifty-two week high of $3.14.

Vor Biopharma (NYSE:VOR) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.40) EPS for the quarter, meeting the consensus estimate of ($0.40). As a group, research analysts predict that Vor Biopharma will post -1.55 earnings per share for the current year.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.